
Permalink
https://escholarship.org/uc/item/2sm573j9

Journal
The American journal of pathology, 189(8)

ISSN
0002-9440

Authors
Bilousova, Tina
Melnik, Mikhail
Miyoshi, Emily
et al.

Publication Date
2019-08-01

DOI
10.1016/j.ajpath.2019.04.010

Copyright Information
This work is made available under the terms of a Creative Commons Attribution License, available at https://creativecommons.org/licenses/by/4.0/

Peer reviewed
appropriate patient selection in clinical trials—medications that delay onset of AD may not be useful in slowing the progression of AD dementia.

Elizabeth Hedlund Corder, PhD
Center for Demographic Studies
Duke University
Durham, NC 27708-0408
Lars Lannfelt, MD, PhD
Hans Basun, MD, PhD
Stockholm, Sweden


In reply

We thank Corder and colleagues for their comments on our recent study1 and we are pleased that they agree with our conclusion that ApoE genotype does not appear to significantly influence rate of cognitive decline in AD. In their letter, Corder et al also raised 2 other issues regarding our study.

The authors correctly note that the study by Corder et al2 did not report "longer survival in e4 carriers." In addition to the study by van Duijn et al3 those findings should have been correctly attributed to DeKosky et al4 and not to Corder et al,2 as indicated by the reference numbers in the text of our article. We apologize for the confusion this oversight created.

Corder et al state that we "argue against the existence of an e4 gene-dose effect on the risk of becoming affected [with AD]." Our study on rate of decline in patients with AD did not address the issue of risk of AD associated with ApoE genotype. We did, however, describe the characteristics of the sample. We noted a trend for an inverted gene-dose effect of e4 on age of symptom onset and, as stated in the discussion section of our article, this trend remained even after excluding subjects with symptom onset before age 60 years. We do not debate the existence of a gene-dose effect on the risk of becoming affected with AD. Other studies have also failed to find the expected difference in age of onset in relation to ApoE genotype (eg, Corder et al2), and the letter of Corder et al offers a clear explanation of the possible reasons. However, the most effective investigation of this issue, as also noted by Corder and colleagues, would be through population-based, prospective studies, some of which are currently in progress.

D. Xeno Rasmusson, PhD
Alzheimer's Disease Research Center
The Johns Hopkins University School of Medicine
Room 1B82
5501 Hopkins Bayview Circle
Baltimore, MD 21224
Gloria Dal Forno, MD
Jason Brandt, PhD
Juan Troncoso MD
Claudia H. Kawas, MD
Baltimore